Tesaro (TSRO) PT Raised to $115 at Leerink Following Full Results of Ph 3 NOVA Trial

October 10, 2016 6:34 AM EDT
Get Alerts TSRO Hot Sheet
Price: $151.25 -3.3%

Rating Summary:
    14 Buy, 2 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 35 | Down: 31 | New: 11
Trade TSRO Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Leerink Partners analyst Seamus Fernandez reiterated an Outperform rating and raised its price target on Tesaro (NASDAQ: TSRO) to $115.00 (from $108.00) after full results of the Ph 3 NOVA trial (niraparib as 2L maintenance for ovarian cancer) presented in a Presidential Session at ESMO and published in the NEJM position niraparib as the new 2L maintenance treatment standard in platinum sensitive ovarian cancer, having demonstrated solid, durable, and statistically significant efficacy with a manageable safety profile regardless of biomarker status (hazard ratios by biomarker status germline BRCA mut + = 0.27; somatic BRCA mut + = 0.27; BRCA wild type HRD+ = 0.38; non-HRD BRCA wt = 0.58).

Fernandez commented, "We believe these data are strong enough to warrant approval in the overall patient population regardless of BRCAmut or HRD status and are increasing our probability of approval in non-gBRCA/HRD-negative patients to 70% in the US (from 0%) and 50% in the EU (from 0%). We reiterate our OP rating and increase our price target to $115/shr (from $108/shr)."

For an analyst ratings summary and ratings history on Tesaro click here. For more ratings news on Tesaro click here.

Shares of Tesaro closed at $99.26 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst PT Change, FDA

Add Your Comment